{"id":"d3abfff2-523e-5c04-b397-8a9c83d56f83","stable_key":"104835a3-b891-5dc4-a6bb-42ab7c6f96c4:butyrate-tcell-conditioning","predicate":"modulates","statement":"In-vitro exposure of CTLs and CAR T cells to butyrate or pentanoate increased mTOR-related activity and inhibited class-I HDAC activity, producing a stronger effector program in the study.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"2e18a72b-152c-58cc-aaca-6f36bb2fb834","mechanism_event_label":"Treating cells outside the body was a different intervention from systemic exposure during checkpoint therapy.","subject":{"id":"e7428a7f-d35a-5406-9904-a88984814833","slug":"butyrate","display_name":"Butyrate","entity_type_key":"small_molecule"},"object":{"id":"33e62581-a693-524c-ad3b-f07424806aa6","slug":"butyrate-conditioned-t-cell-product","display_name":"Ex-vivo butyrate-conditioned cytotoxic T-cell product; species specified","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"2e18a72b-152c-58cc-aaca-6f36bb2fb834","stable_key":"104835a3-b891-5dc4-a6bb-42ab7c6f96c4:butyrate-tcell-conditioning-event","event_type":"observed_relationship","label":"Treating cells outside the body was a different intervention from systemic exposure during checkpoint therapy.","description":"In-vitro exposure of CTLs and CAR T cells to butyrate or pentanoate increased mTOR-related activity and inhibited class-I HDAC activity, producing a stronger effector program in the study.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e7428a7f-d35a-5406-9904-a88984814833","slug":"butyrate","display_name":"Butyrate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"33e62581-a693-524c-ad3b-f07424806aa6","slug":"butyrate-conditioned-t-cell-product","display_name":"Ex-vivo butyrate-conditioned cytotoxic T-cell product; species specified","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Ex-vivo cytotoxic T-cell programming with preclinical cellular-therapy experiments; species recorded in the primary study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The accessed abstract groups two SCFAs and multiple cell products; do not assign every in-vivo benefit exclusively to butyrate or claim oral supplementation improves CAR T therapy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Butyrate collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"butyrate","display_name":"Butyrate","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Treating cells outside the body was a different intervention from systemic exposure during checkpoint therapy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34210970/ · DOI 10.1038/s41467-021-24331-1","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d06d1d15-b160-528e-b0d5-518032bc58c6","evidence_kind":"source_excerpt","locator":"Lines 670-676","start_line":670,"end_line":676,"excerpt":"## butyrate-tcell-conditioning\nTreating cells outside the body was a different intervention from systemic exposure during checkpoint therapy.\nIn-vitro exposure of CTLs and CAR T cells to butyrate or pentanoate increased mTOR-related activity and inhibited class-I HDAC activity, producing a stronger effector program in the study.\nModel: Ex-vivo cytotoxic T-cell programming with preclinical cellular-therapy experiments; species recorded in the primary study.\nLimitations: The accessed abstract groups two SCFAs and multiple cell products; do not assign every in-vivo benefit exclusively to butyrate or claim oral supplementation improves CAR T therapy.\nEvidence access: Primary abstract\nMicrobial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34210970/ · DOI 10.1038/s41467-021-24331-1","model_system":"Ex-vivo cytotoxic T-cell programming with preclinical cellular-therapy experiments; species recorded in the primary study.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"33205bb8-dcbe-5d2c-afca-86075d7748d1","stable_key":"import-104835a3-b891-5dc4-a6bb-42ab7c6f96c4","title":"Butyrate: microbial production, fuel use, signaling and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"a1253eb4426fc45d7b7c113028aa4ba2e9f89a9653272f3795437fc222bad558","revision_id":"c2320e65-a252-57a9-8838-7abf3d23400e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}